A Registry for People With Lung Cancer

This is an observational study, meaning it collects information without testing a new treatment. It's for people with lung cancer, specifically those with Stage I disease, who are having a surgery called pulmonary segmentectomy. The study aims to understand how many participants are free of disease after 3 and 5 years. You would complete questionnaires using a web-based platform called Patient-Reported Outcomes Measurement Information System (PROMIS) before and after your surgery. The study is currently unclear on its recruitment status and plans to enroll 600 participants.

Study design: This is an observational study, not testing a specific treatment. It plans to enroll 600 participants.
What's involved: You will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.
Compensation: Not stated in the trial record.
Follow-up: Participants will be followed to determine disease-free survival at 3 and 5 years after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

A Registry for People With Lung Cancer

Recruiting

Not specifiedAges 18+Observational

Memorial Sloan Kettering Cancer Center

~600 participants

Updated 2026-08-07 on ClinicalTrials.gov

What's tested:Patient-Reported Outcomes Measurement Information System

At a glance

Recruiting sites

18 of 18 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Determine 3-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.

Measured over 3 years

+1 more outcome measured

Conditions

Lung Cancer

Lung Cancer Stage I

Where it's being run

18 sites across 10 states

New York4

New Jersey3

Illinois2

Pennsylvania2

Texas2

Arizona1

California1

Michigan1

Study leadership

David Jones, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

David Jones, MD

[email protected]

212-639-6428

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Age ≥18 years

Patients suitable for segmentectomy, according to the treating surgeon

Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology

Exclusion

Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years

History of chemotherapy or radiation therapy for a previous lung cancer

Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery

Carcinoid tumors

History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix

Actively receiving treatment for other malignancies

Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis.

Multi-segmental resection from the same lobe is not a criterion for exclusion.

What this trial measures

Determine 3-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.3 years
DFS is measured from the date of surgery to the date of recurrence or death
Determine 5-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.5 years
DFS is measured from the date of surgery to the date of recurrence or death

Trialytics